您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版)

• 论文 • 上一篇    下一篇

卡培他滨增敏联合后程加速超分割放射治疗食管癌的疗效观察

韩春燕,盛巍,韩俊庆   

  1. 山东大学附属省立医院肿瘤中心, 济南 250021
  • 收稿日期:2007-11-07 修回日期:1900-01-01 出版日期:2008-04-16 发布日期:2008-04-16
  • 通讯作者: 韩俊庆

Capecitabine combined with late course accelerated hyperfractionatedradiotherapy for esophageal cancer

HAN Chun-yan, SHENG Wei, HAN Jun-qing   

  1. Department of Oncology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
  • Received:2007-11-07 Revised:1900-01-01 Online:2008-04-16 Published:2008-04-16
  • Contact: HAN Jun-qing

摘要: 目的探讨口服卡培他滨增敏联合后程加速超分割(简称后超)放射治疗食管癌的近期疗效、生存期及毒副反应。方法将82例食管癌患者随机分为后超+卡培他滨组(治疗组)和单纯后超组(对照组)。放疗前2/3疗程常规分割,即2Gy/次,5次/周,共40Gy,后1/3疗程1.5Gy/次,2次/d,间隔6h或以上,5d/周,总剂量65~70Gy。治疗组自放疗第1d开始口服卡培他滨1000mg/m2,2次/d,连续服用14d,休息7d,治疗周期为21d,共治疗2个周期。结果82例患者全部完成治疗计划,治疗组和对照组近期疗效分别为89.7%和76.9%,差异有统计学意义(P<0.05),1年生存率分别为80.5%和73.2%(P>0.05),放射性食管炎和骨髓抑制的发生率,两组差异无统计学意义。结论口服卡培他滨增敏联合后程加速超分割放疗可提高食管癌的近期疗效,未增加毒副反应,耐受性良好,远期疗效仍需进一步观察。

Abstract: To evaluate the response, survival and toxicity of capecitabine combined with late course accelerated hyperfractionated radiotherapy(LCAHR) for esophageal cancer. MethodsEightytwo patients were randomly divided into two groups: 41 patients in the treatment group received capecitabine combined with LCAHR, and the other 41 patients in the control group received LCAHR only. All patients were treated by conventional fractionated radiotherapy during the first twothirds of the whole course with 40?Gy in 20 fractions, followed by LCAHR with 2530?Gy in 1719 fractions, 1.5?Gy per fraction, twice a day, with an interval of more than 6 hours between fractions to a total dose of 6570?Gy. The treatment group took 1?000?mg/m2 capecitabine twice a day for fourteen days followed by a 7day rest period from the first day of radiotherapy, every 3 weeks as one cycle, totally 2 cycles. ResultsAll patients completed treatment courses. The shortterm response rate of the treatment group and the control group was 89.7% and 76.9% respectively with statistically significant differences. The 1year survival rate was 80.5% and 73.2% in the treatment and control groups respectively(P>0.05). As for acute radiation esophagitis and myelosuppression, there were no significant differences between the two groups. ConclusionCapecitabine combined with late course accelerated hyperfractionated radiotherapy for esophageal cancer can improve the shortterm response rate. Its side effects are not statistically different from those of the LCAHR alone and are tolerable, however its longterm results need further study in clinic.

Key words: Esophageal neoplasms, Radiotherapy, Drug therapy, Dose fractionation

中图分类号: 

  • R735.1
[1] 王玉红,张丽红,王林省,陈月芹,王彦辉,王皆欢,李传福. 消化道颗粒细胞瘤的影像学表现[J]. 山东大学学报(医学版), 2017, 55(8): 66-70.
[2] 韩福燕,成士清,王召宝,鞠瑛. 食管癌患者外周血红细胞分布宽度检测的临床价值[J]. 山东大学学报(医学版), 2017, 55(7): 67-72.
[3] 张明明,安永辉,韩彩莉,张瑛琪,马明,李娜,邹长鹏. CIK细胞联合光动力治疗中晚期食管癌的疗效观察[J]. 山东大学学报(医学版), 2016, 54(1): 38-41.
[4] 李帅1,吴洪磊1,周成军2,郭建强1. APC和β-catenin在食管胃连接部病变中的表达及意义[J]. 山东大学学报(医学版), 2014, 52(3): 27-32.
[5] 樊智彬1,于卫芳2,张丽静1,刘博1,吴晨鹏3,张学明4,赵增仁1. microRNA-150在结直肠癌组织中的表达及临床意义[J]. 山东大学学报(医学版), 2013, 51(11): 85-89.
[6] 刘莺,李克,徐淑宁,刘文静,侯新芳,王居峰. SphK1与食管癌侵袭和转移的关系[J]. 山东大学学报(医学版), 2012, 50(9): 21-.
[7] 李强,杨哲,赵瑛,韩俊庆. EGFR对食管癌同步放化疗敏感性预测价值的初步观察[J]. 山东大学学报(医学版), 2012, 50(3): 96-.
[8] 张振伟1,蒋仲敏2. Mel-18 mRNA在食管鳞癌中的表达及其临床意义[J]. 山东大学学报(医学版), 2012, 50(2): 78-.
[9] 贾慧1,2,于金明2,宋平平3,张为迪3,穆殿斌4,韩大力2,张锡芹2. 术前新辅助放化疗对食管癌原发灶病理形态学及Ki-67表达的影响[J]. 山东大学学报(医学版), 2011, 49(7): 125-.
[10] 郝小蕊,卢雪峰,孙娜,刘胜楠,刘亮 . 诱骗受体3在食管鳞癌中的表达及其与肿瘤浸润T细胞的关系[J]. 山东大学学报(医学版), 2011, 49(6): 134-.
[11] 张好1,周英智2,刁玉涛3,李会庆3,周瑞雪4,赵德利4,雷复华4. 男性食管癌影响因素的病例对照研究[J]. 山东大学学报(医学版), 2010, 48(11): 102-105.
[12] 孙晓宏, 庞作良, 罗洞波. MMP-2及MMP-7在食管癌及癌旁组织中的表达[J]. 山东大学学报(医学版), 2010, 48(7): 102-104.
[13] 田光亮1,邱晨1,王俊超2,郝澄澄3,王娇1,刘慧忠1. 食管癌放射治疗中肿瘤退缩速度与预后的关系[J]. 山东大学学报(医学版), 2010, 48(2): 136-139.
[14] 付卫江,杨秋安,韩文斐,付雷,高爽,潘振华,程孝国 . 同时放化疗治疗晚期食管癌的临床研究[J]. 山东大学学报(医学版), 2008, 46(1): 84-87.
[15] 王湘连,刘慧忠,乔乃安,郝澄澄,王俊超. 爱维治防治急性放射性食管炎的临床研究[J]. 山东大学学报(医学版), 2007, 45(11): 1133-1138.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!